340B Drug Pricing Program
The Department of Health and Human Services will begin restoring a payment rate of average sales price plus 6% for 340B drug claims in about two weeks, the department told a United States District Court for the District of Columbia.
The United States District Court for the District of Columbia Sept 28 ruled in favor of the AHA, holding that the Department of Health and Human Services must immediately halt the departments’ unlawful cuts to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that…
The AHA appreciates Judge Contreras’ ruling that the Department of Health and Human Services must immediately stop unlawful reimbursement cuts for 2022 for hospitals participating in the 340B drug pricing program. Halting these cuts will help 340B hospitals provide comprehensive health services to…
The United States District Court for the District of Columbia today ruled in favor of the AHA, holding that the Department of Health and Human Services must immediately halt the departments’ unlawful cuts to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that…
The United States District Court for the District of Columbia ruled in favor of the AHA, holding that HHS must immediately halt the departments’ unlawful cuts to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that participate in the 340B Drug Pricing Program.
This page contains materials related to AHA’s current and active policy-related litigation.
Judge orders HHS to immediately halt unlawful reimbursement cuts for remainder of 2022 re: 340B.
340B Advocacy Alliance Bulletin for September 27, 2022.
340B Advocacy Alliance Bulletin for September 23, 2022.
Forty-six days from now on Nov. 8 millions of Americans will cast their ballots and exercise their most sacred right – the right to vote.